ABSTRACT
Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been used experimentally in patients with acute respiratory distress syndrome. Recombinant GM-CSF administered by direct inhalation is currently being studied in a cohort of patients with advanced COVID-19.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
- Leonard H. Calabrese, DO⇑
- Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute, Cleveland Clinic
- Correspondence:
Leonard H. Calabrese, DO, Department of Rheumatic and Immunologic Diseases, A50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; calabrl{at}ccf.org
- Tiphaine Lenfant, MD
- Cassandra Calabrese, DO
ABSTRACT
Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been used experimentally in patients with acute respiratory distress syndrome. Recombinant GM-CSF administered by direct inhalation is currently being studied in a cohort of patients with advanced COVID-19.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.